.
10 For reviews, see: (a) Sachs, G.; Shin, J. M.; Howden, C. W.AlimentPharmacol. Ther.2006,23, 2(b) Tonini, M.; Giorgio, R, D.; Ponti, F. D.Expert Opin. Ther:Patents2003,13, 639
13 HPLC data: Chiral pack AD 50 mm x 4.6 mm or equivalent, flow rate0.5 mL/min with a UV detector at 280 nm, load 20 μL, runtime 30 minat 25-30 °C.
Factors Influencing the Selectivity in symmetric
Factors Influencing the Selectivity in symmetric
Oxidation of Sulfides Attached to Nitrogen
Containing Heterocycles
Muthu Seenivasaperumal,aHans-Jürgen Federsel,bAnne Ertanbcand Kálmán J. Szabóa*a
a Stockholm University, Arrhenius Laboratory, Department of Organic Chemistry
SE-106 91 Stockholm, Sweden;
b
Global Process R&D and
c
Early Development,
Pharmaceutical and Analytical R&D, AstraZeneca, SE-151 85 Södertälje, Sweden
E-mail: kalman@organ.su.se. Fax: +46-8-15 49 08
REF 8
Cotton, H.; Elebring, T.; Larsson, M.; Li, L.; Sörensen, H.; von Unge, S.Tetrahedron: Asymmetry2000,11,3819
Derivative Type: S-Form
CAS Registry Number: 119141-88-7
Additional Names: Esomeprazole; perprazole
Manufacturers' Codes: H-199/18
Literature References: LC-MS determn in plasma: H. Stenhoff et al., J. Chromatogr. B 734, 191 (1999).
Properties: Colorless syrup. [a]D20 -155° (c = 0.5 in chloroform).
Optical Rotation: [a]D20 -155° (c = 0.5 in chloroform)
Derivative Type: S-Form magnesium salt
CAS Registry Number: 161973-10-0
CAS Name: (T-4)-Bis[5-methoxy-2-[(S)-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazolato]magnesium
Additional Names: esomeprazole magnesium
Trademarks: Nexium (AstraZeneca)
Literature References: Review of clinical experience in acid disorders: D. A. Johnson, Expert Opin. Pharmacother. 4, 253-264 (2003).
Properties: White powder. [a]D20 -128.2° (c = 1 in methanol).
Optical Rotation: [a]D20 -128.2° (c = 1 in methanol)
Therap-Cat: Antiulcerative; in treatment of Zollinger-Ellison syndrome.
Therap-Cat-Vet: Antiulcerative.
Keywords: Antiulcerative; Gastric Proton Pump Inhibitor.
REF
/////////
IRAN FOOD, IRAN, PERSIAN FOOD, PERSIA
/////////
No comments:
Post a Comment